Dr Jill Corre speaks to ecancer about a new classification for identifying HR myeloma based on cytogenetic abnormalities.
Genetic risk factors significantly influence patient stratification and treatment strategies.
Recent advancements emphasise the importance of a genomic consensus that identifies specific mutations affecting treatment decisions.
The complexity of diseases, with various high-risk subgroups, necessitates collaboration among clinicians.
Effective communication and data sharing are vital, while challenges with next-generation sequencing technology and the FISH technique for mutation detection are also addressed.